Reaching the SDG targets on Health by 2030: ECDC Session at European Health Forum Gastein 2018
Will we reach the United Nations Sustainable Development Goal (SDG) for health by 2030 and the targets set for HIV/AIDS, hepatitis and tuberculosis? ECDC’s session at the European Health Forum Gastein looks at the action required to end AIDS and TB, and to combat hepatitis.
Epidemiological update: Hepatitis A outbreak in the EU/EEA mostly affecting men who have sex with men
As of 7 September 2018, the number of outbreak-confirmed cases reported in 22 EU/EEA countries since 1 June 2016 is 4 475.
World Hepatitis Day 2018
On the occasion of World Hepatitis Day, ECDC launched online prevalence database for hepatitis B and C which included data mainly based on peer-reviewed cross sectional studies from 2006 onwards.
Preventing blood-borne viruses in prison settings: ECDC and EMCDDA Guidance
In their joint public health guidance published today at AIDS 2018, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) outline evidence-based and effective measures to help prevent and control the transmission of blood-borne viruses in prison settings.
ECDC and EMCDDA make the case for active case finding of communicable diseases in prison
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.
ECDC-EMCDDA review: Can active case finding help reduce communicable diseases in prisons?
ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) have systematically retrieved and assessed evidence on active case findings for blood-borne viruses like HIV, hepatitis B and C, sexually transmitted infections as well as tuberculosis in prison settings in the EU/EEA.
Gaps in hepatitis testing and monitoring programmes across the EU/EEA: ECDC survey
The survey results suggest a wide variation in existing national testing policy and practice when it comes to hepatitis B and C – with overall limited monitoring of testing, diagnosis, and treatment across EU/EEA Member States. Many respondents expressed a need for Europe-wide practical guidance on how testing initiatives should be conducted, evaluated, and monitored.
Epidemiological update: Hepatitis A outbreaks in the EU/EEA mostly affecting men who have sex with men
Since the last ECDC rapid risk assessment, which was published on 24 February 2017, 10 EU Member States (Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Portugal, Sweden and the United Kingdom (Public Health England and Health Protection Scotland) reported 387 new confirmed cases of hepatitis A, with one of the strains matching the three clusters currently circulating in the EU.
Taking stock: where does Europe stand in the elimination of hepatitis B and C?
In 2016, a regional action plan for Europe that aims to contribute to the implementation of the global viral hepatitis elimination strategy was developed by the WHO Regional Office for Europe. In an article published today in Eurosurveillance, the authors take a closer look how Europe is doing according to the ten indicators and targets outlined in this plan. In short: Europe still has some way to go if it wants to eliminate viral hepatitis by 2030.